Literature DB >> 36254020

Clinicopathological characteristics, survival outcomes and prognostic factors in the cT1N0M0 pancreatic neuroendocrine tumors: A SEER-based study.

Nian Guo1, Zhen Liang2, Li Jiao Xiong3.   

Abstract

Small nonfunctional pancreatic neuroendocrine tumors ≤2 cm have different biological features, and there is no gold standard treatment for them. This study aimed to assess the risk of malignancy of small non-functional pancreatic neuroendocrine tumors and their outcomes after radical resection. The optimal management of small, incidentally detected pancreatic neuroendocrine tumors is controversial, with the aim of identifying factors predicting survival in patients with clinical stage T1N0M0 (cT1N0M0) pancreatic neuroendocrine tumors and whether surgical treatment improves survival. Using the Surveillance, Epidemiology, and End Results database, we identified 637 patients with cT1N0M0 pancreatic neuroendocrine tumors from 2010 to 2015, including clinicopathological characteristics, treatment modalities, and outcome data. From the surveillance, epidemiology, and end results database of 637 patients with cT1N0M0 PNENs, 564 were treated surgically. Age (P = .000), sex (P < .001), and surgery (P < .001) were independent risk factors affecting survival. Patients who have undergone surgery, women and young adults have a higher overall survival rate. The following independent prognostic predictors for cT1N0M0 pNENs were identified: age, sex, and surgery. At last, we concluded that Surgery can increase the overall survival of pancreatic neuroendocrine tumors in T1N0M0.
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Year:  2022        PMID: 36254020      PMCID: PMC9575711          DOI: 10.1097/MD.0000000000031019

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  21 in total

1.  Implementation of Current ENETS Guidelines for Surgery of Small (≤2 cm) Pancreatic Neuroendocrine Neoplasms in the German Surgical Community: An Analysis of the Prospective DGAV StuDoQ|Pancreas Registry.

Authors:  Ioannis Mintziras; Tobias Keck; Jens Werner; Stefan Fichtner-Feigl; Uwe Wittel; Norbert Senninger; Thorsten Vowinkel; Jörg Köninger; Matthias Anthuber; Bernd Geißler; Detlef Klaus Bartsch
Journal:  World J Surg       Date:  2019-01       Impact factor: 3.352

2.  Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  M Pavel; K Öberg; M Falconi; E P Krenning; A Sundin; A Perren; A Berruti
Journal:  Ann Oncol       Date:  2020-04-06       Impact factor: 32.976

Review 3.  Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms.

Authors:  S Partelli; R Cirocchi; S Crippa; L Cardinali; V Fendrich; D K Bartsch; M Falconi
Journal:  Br J Surg       Date:  2016-10-05       Impact factor: 6.939

4.  Prognostic Assessment of Non-functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk-Adapted Resection Strategies.

Authors:  F M Watzka; F Meyer; J I Staubitz; C Fottner; A Schad; H Lang; T J Musholt
Journal:  World J Surg       Date:  2020-02       Impact factor: 3.352

5.  New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors: A Multi-institutional and National Data Analysis.

Authors:  Xu-Feng Zhang; Feng Xue; Ding-Hui Dong; Alexandra G Lopez-Aguiar; George Poultsides; Eleftherios Makris; Flavio Rocha; Zaheer Kanji; Sharon Weber; Alexander Fisher; Ryan Fields; Bradley A Krasnick; Kamran Idrees; Paula M Smith; Cliff Cho; Megan Beems; Yi Lv; Shishir K Maithel; Timothy M Pawlik
Journal:  Ann Surg       Date:  2021-07-01       Impact factor: 12.969

6.  Sporadic nonfunctional pancreatic neuroendocrine tumors: Risk of lymph node metastases and aggressiveness according to tumor size: A multicenter international study.

Authors:  Julie Perinel; Gennaro Nappo; Alessandro Zerbi; Charlotte M Heidsma; Elisabeth J M Nieveen van Dijkum; Ho Seong Han; Yoo-Seok Yoon; Sohei Satoi; Ihsan Ekin Demir; Helmut Friess; Yogesh Vashist; Jakob Izbicki; Alexandra Charlotte Muller; Beat Gloor; Marta Sandini; Luca Gianotti; Fabien Subtil; Mustapha Adham
Journal:  Surgery       Date:  2022-05-24       Impact factor: 4.348

7.  NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.

Authors:  Manisha H Shah; Whitney S Goldner; Thorvardur R Halfdanarson; Emily Bergsland; Jordan D Berlin; Daniel Halperin; Jennifer Chan; Matthew H Kulke; Al B Benson; Lawrence S Blaszkowsky; Jennifer Eads; Paul F Engstrom; Paul Fanta; Thomas Giordano; Jin He; Martin J Heslin; Gregory P Kalemkerian; Fouad Kandeel; Sajid A Khan; Wajih Zaheer Kidwai; Pamela L Kunz; Boris W Kuvshinoff; Christopher Lieu; Venu G Pillarisetty; Leonard Saltz; Julie Ann Sosa; Jonathan R Strosberg; Craig A Sussman; Nikolaos A Trikalinos; Nataliya A Uboha; Jonathan Whisenant; Terence Wong; James C Yao; Jennifer L Burns; Ndiya Ogba; Griselda Zuccarino-Catania
Journal:  J Natl Compr Canc Netw       Date:  2018-06       Impact factor: 11.908

8.  Behavior of Small, Asymptomatic, Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PNETs).

Authors:  Jae Gu Jung; Kyu Taek Lee; Young Sik Woo; Jong Kyun Lee; Kwang Hyuck Lee; Kee-Taek Jang; Jong Chul Rhee
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

9.  Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors.

Authors:  Zheng Zhang; Fei Wang; Zheng Li; Zeng Ye; Qifeng Zhuo; Wenyan Xu; Wensheng Liu; Mengqi Liu; Guixiong Fan; Yi Qin; Yue Zhang; Xuemin Chen; Xianjun Yu; Xiaowu Xu; Shunrong Ji
Journal:  BMC Surg       Date:  2022-05-10       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.